QuidelOrtho Corporation

QuidelOrtho Corporation is a global leader in in vitro diagnostics (IVD), dedicated to developing and manufacturing innovative diagnostic healthcare products. The company's mission is to enhance the performance of diagnostic testing to improve patient outcomes across the entire healthcare continuum. Headquartered in San Diego, California, QuidelOrtho operates with a worldwide presence, serving diverse healthcare settings.

QuidelOrtho's comprehensive portfolio spans immunoassay and molecular testing, clinical chemistry, and transfusion medicine. Key product offerings include instruments, reagents, and assays under brands such as Sofia, QuickVue, Triage, VITROS Systems, ORTHO VISION Systems, and Savanna. These solutions cater to a broad range of market segments, including point-of-care settings, clinical laboratories, hospitals, physician offices, reference laboratories, urgent care clinics, blood banks, and donor centers, providing both professional and over-the-counter diagnostic options.

As one of the world's largest IVD providers, QuidelOrtho was formed in May 2022 through the combination of Quidel Corporation and Ortho Clinical Diagnostics. Recent notable developments include the completion of the acquisition of LEX Diagnostics in April 2026, which integrated the LEX VELO molecular diagnostics platform for rapid multiplex RT-PCR testing for respiratory infections. The company also announced its preliminary first-quarter 2026 revenue and updated full-year guidance, and appointed Nathaniel Sisitsky as Chief Legal Officer in March 2026. In February 2024, Michael Iskra was appointed interim CEO, replacing Douglas Bryant.